The Influence of Maternal Exposure History to Virus and Medicine During Pregnancy on Congenital Heart Defects of Fetus

Overview

Journal Environ Sci Pollut Res Int

Publisher Springer

Specialties Environmental Health
Toxicology

Date 2017 Jan 1

PMID 28039625

Citations 13

Authors

Qianhong Liang

Wei Gong

Dongming Zheng

Risheng Zhong

Yunjie Wen

Xiaodan Wang

Affiliations

Soon will be listed here.

Abstract

Congenital heart disease (CHD) is the most common birth defect. It is due to dysfunction of the heart and great vessels during embryo development stage, or the channel was not closed after birth. This study focuses on investigating the influence of virus infection and medicine history during pregnancy on the incidence rate of CHD of fetus. We conducted a retrospective birth cohort study of infant born in the maternal and child health hospital of Fanyu district in Guangzhou. Five thousand three hundred eighty one cases with complete medical records, including mothers, fathers, and infants, were enrolled. The exposure history of mothers to virus and medicine from 6 months before pregnancy to prenatal examination was investigated, including mflu, mumps, measles, rubella, chickenpox, and hepatitis and antibiotics, tocolytic agent, anticonvulsants, antipyretic and analgesic, antitumor drug, folic acid supplement, and contraceptive. The relationship between virus infection and medicine history during pregnancy and CHD was analyzed. There was statistical difference between a normal group and a defected group in influenza infection and tocolytic agent and contraceptive pill. The exposure history to influenza and medicines, such as tocolytic agent and contraceptive pill, during pregnancy influenced the incidence rate of CHD of fetus.

Citing Articles

Global, regional, and national burden of congenital heart disease, 1990-2021: a systematic analysis for the global burden of disease study 2021.

Zhang X, Feng Y, Ren J, Jin X, Li J, Hou Y Eur J Pediatr. 2025; 184(4):253.

PMID: 40088268 DOI: 10.1007/s00431-025-06085-w.

Risk and protective factors related to having a child with congenital heart diseases (CHD): a case-control study in Iran.

Amini-Rarani M, Karimi S, SoleimanvandiAzar N, Nosratabadi M Front Pediatr. 2023; 11:1170743.

PMID: 37492609 PMC: 10365085. DOI: 10.3389/fped.2023.1170743.

Maternal Preconception Hepatitis B Virus Infection and Risk of Congenital Heart Diseases in Offspring Among Chinese Women Aged 20 to 49 Years.

Wu H, Yang Y, Jia J, Guo T, Lei J, Deng Y JAMA Pediatr. 2023; 177(5):498-505.

PMID: 36912830 PMC: 10012042. DOI: 10.1001/jamapediatrics.2023.0053.

The association between folic acid supplementation and congenital heart defects: Systematic review and meta-analysis.

Wondemagegn A, Afework M SAGE Open Med. 2022; 10:20503121221081069.

PMID: 35284077 PMC: 8905196. DOI: 10.1177/20503121221081069.

Maternal Viral Infection in Early Pregnancy and Risk of Congenital Heart Disease in Offspring: A Prospective Cohort Study in Central China.

Wang T, Li Q, Chen L, Ni B, Sheng X, Huang P Clin Epidemiol. 2022; 14:71-82.

PMID: 35082532 PMC: 8784951. DOI: 10.2147/CLEP.S338870.

References

Shi H, Yang S, Liu Y, Huang P, Lin N, Sun X . Study on Environmental Causes and SNPs of MTHFR, MS and CBS Genes Related to Congenital Heart Disease. PLoS One. 2015; 10(6):e0128646. PMC: 4452709. DOI: 10.1371/journal.pone.0128646. View

NORA J . Multifactorial inheritance hypothesis for the etiology of congenital heart diseases. The genetic-environmental interaction. Circulation. 1968; 38(3):604-17. DOI: 10.1161/01.cir.38.3.604. View

Lin K, Mitchell A, Yau W, Louik C, Hernandez-Diaz S . Safety of macrolides during pregnancy. Am J Obstet Gynecol. 2012; 208(3):221.e1-8. PMC: 3581717. DOI: 10.1016/j.ajog.2012.12.023. View

Cooper W, Hernandez-Diaz S, Arbogast P, Dudley J, Dyer S, Gideon P . Antibiotics potentially used in response to bioterrorism and the risk of major congenital malformations. Paediatr Perinat Epidemiol. 2009; 23(1):18-28. PMC: 3381893. DOI: 10.1111/j.1365-3016.2008.00978.x. View

Autti-Ramo I, Fagerlund A, Ervalahti N, Loimu L, Korkman M, Hoyme H . Fetal alcohol spectrum disorders in Finland: clinical delineation of 77 older children and adolescents. Am J Med Genet A. 2005; 140(2):137-43. DOI: 10.1002/ajmg.a.31037. View

Acs N, Banhidy F, Puho E, Czeizel A . Maternal influenza during pregnancy and risk of congenital abnormalities in offspring. Birth Defects Res A Clin Mol Teratol. 2005; 73(12):989-96. DOI: 10.1002/bdra.20195. View

Oster M, Riehle-Colarusso T, Correa A . An update on cardiovascular malformations in congenital rubella syndrome. Birth Defects Res A Clin Mol Teratol. 2009; 88(1):1-8. DOI: 10.1002/bdra.20621. View

Smith T, Rajakaruna C, Caputo M, Emanueli C . MicroRNAs in congenital heart disease. Ann Transl Med. 2016; 3(21):333. PMC: 4690991. DOI: 10.3978/j.issn.2305-5839.2015.12.25. View

Wang X, Li P, Chen S, Xi L, Guo Y, Guo A . Influence of genes and the environment in familial congenital heart defects. Mol Med Rep. 2013; 9(2):695-700. DOI: 10.3892/mmr.2013.1847. View

10.

Kallen B, Olausson P . Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol. 2003; 17(3):255-61. DOI: 10.1016/s0890-6238(03)00012-1. View

11.

Oster M, Riehle-Colarusso T, Alverson C, Correa A . Associations between maternal fever and influenza and congenital heart defects. J Pediatr. 2011; 158(6):990-5. DOI: 10.1016/j.jpeds.2010.11.058. View

12.

Rosenberg H . Cardiovascular effects of congenital infections. Am J Cardiovasc Pathol. 1987; 1(2):147-56. View

13.

Czeizel A, Puho E, Acs N, Banhidy F . High fever-related maternal diseases as possible causes of multiple congenital abnormalities: a population-based case-control study. Birth Defects Res A Clin Mol Teratol. 2007; 79(7):544-51. DOI: 10.1002/bdra.20369. View

14.

van der Linde D, Konings E, Slager M, Witsenburg M, Helbing W, Takkenberg J . Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J Am Coll Cardiol. 2011; 58(21):2241-7. DOI: 10.1016/j.jacc.2011.08.025. View

15.

Kallen B, Olausson P, Danielsson B . Is erythromycin therapy teratogenic in humans?. Reprod Toxicol. 2005; 20(2):209-14. DOI: 10.1016/j.reprotox.2005.01.010. View

16.

Burdan F, Szumilo J, Dudka J, Korobowicz A, Klepacz R . Congenital ventricular septal defects and prenatal exposure to cyclooxygenase inhibitors. Braz J Med Biol Res. 2006; 39(7):925-34. DOI: 10.1590/s0100-879x2006000700011. View

17.

Oberlander T, Warburton W, Misri S, Riggs W, Aghajanian J, Hertzman C . Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol. 2008; 83(1):68-76. DOI: 10.1002/bdrb.20144. View

18.

Feldkamp M, Meyer R, Krikov S, Botto L . Acetaminophen use in pregnancy and risk of birth defects: findings from the National Birth Defects Prevention Study. Obstet Gynecol. 2009; 115(1):109-115. DOI: 10.1097/AOG.0b013e3181c52616. View